{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:26:12Z","timestamp":1790234772975,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijpddr.2019.11.004","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T18:01:02Z","timestamp":1576000862000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"special_numbering":"C","title":["Current trends in the pharmacological management of Chagas disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Vanessa","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayra","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta\u00eds","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Hagstr\u00f6m-Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjar","family":"Nitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2019.11.004_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10822-016-9903-6","article-title":"Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning","author":"Albercal","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.11.004_bib2","first-page":"95","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib3","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/jac\/dkt135","article-title":"Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up","author":"Apt","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib4","first-page":"1","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","author":"Bahia","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib5","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/AAC.02754-13","article-title":"Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease","author":"Bahia","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ijpddr.2019.11.004_bib6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3390\/molecules24071299","article-title":"Chemical constituents of Anacardium occidentale as inhibitors of Trypanosoma cruzi sirtuins","volume":"24","author":"Bastos","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijpddr.2019.11.004_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/bj2860009","article-title":"Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures","volume":"286","author":"Benson","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2017.08.004","article-title":"Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment","author":"Bocchi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijpddr.2019.11.004_bib9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bcp.2010.02.009","article-title":"Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?","volume":"79","author":"Boiani","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/AAC.00617-13","article-title":"Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease","author":"Branquinho","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijpddr.2019.11.004_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas disease chemotherapy","volume":"97","author":"Coura","year":"2002","journal-title":"Mem\u00f3rias do Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib12","first-page":"40","article-title":"Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery","volume":"31","author":"Coura","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4269\/ajtmh.13-0574","article-title":"Mortality due to Chagas disease in Brazil according to a specific cause","author":"Da N\u00f3brega","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.exppara.2015.05.012","article-title":"In vivo and in vitro auranofin activity, against Trypanosoma cruzi: possible new uses for an old drug","author":"Da Silva","year":"2016","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib15","first-page":"3444","article-title":"Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method","author":"Da Silva","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02156-18","article-title":"Imidazole derivatives as promising agents for the treatment of Chagas disease","author":"De Ara\u00fajo","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ijpddr.2019.11.004_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2012.09.018","article-title":"Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi","volume":"41","author":"Moreira","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib18","article-title":"Fexinidazole: first global approval","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib19","series-title":"Chemotherapy of Chagas' Disease: State of the Art and Perspectives for the Development of New Drugs","first-page":"2444","author":"Dias","year":"2009"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib20","series-title":"Brazilian Consensus on Chagas Disease, 2015","first-page":"7","author":"Dias","year":"2016"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib21","first-page":"1","article-title":"Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments","author":"de Figueiredo Diniz","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exppara.2019.02.016","article-title":"Cordycepin (3\u2032-deoxyadenosine) and pentostatin (deoxycoformycin) against Trypanosoma cruzi","volume":"199","author":"Do Carmo","year":"2019","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S0031182013000103","article-title":"Use of clomipramine as chemotherapy of the chronic phase of Chagas disease","author":"Fauro","year":"2013","journal-title":"Parasitology"},{"issue":"1","key":"10.1016\/j.ijpddr.2019.11.004_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s40409-018-0165-8","article-title":"Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study","volume":"24","author":"Ferreira","year":"2018","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"issue":"10","key":"10.1016\/j.ijpddr.2019.11.004_bib25","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.drudis.2016.06.021","article-title":"Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective","volume":"21","author":"Ferreira","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.04.040","article-title":"Effects of resveratrol on the differentiation fate of neural progenitor cells of mouse embryos infected with Trypanosoma cruzi","author":"Fracasso","year":"2019","journal-title":"Microb. Pathog."},{"issue":"8","key":"10.1016\/j.ijpddr.2019.11.004_bib27","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of posaconazole to cure both acute and chronic trypanosoma cruzi infections revealed by highly sensitive in vivo imaging","volume":"59","author":"Francisco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijpddr.2019.11.004_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/srep35351","article-title":"Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage","volume":"6","author":"Francisco","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exppara.2018.04.009","article-title":"Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from Piper jericoense","volume":"189","author":"Garc\u00eda-Huertas","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib30","first-page":"1","article-title":"Simvastatin attenuates endothelial activation through 15-epi-lipoxin A4 production in murine chronic Chagas cardiomyopathy","author":"Gonz\u00e1lez-Herrera","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib31","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.8b00253","article-title":"Successful aspects of the Co-administration of sterol 14\u03b1-demethylase inhibitor VFV and benznidazole in experimental mouse models of Chagas disease caused by the drug-resistant strain of Trypanosoma cruzi","author":"Guedes da Silva","year":"2019","journal-title":"ACS Infect. Dis."},{"issue":"15","key":"10.1016\/j.ijpddr.2019.11.004_bib32","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib33","doi-asserted-by":"crossref","first-page":"31602","DOI":"10.1074\/jbc.M113.497990","article-title":"Complexes of Trypanosoma cruzi sterol 14\u03b1-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease","author":"Hargrove","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ijpddr.2019.11.004_bib34","article-title":"Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy","volume":"113","author":"Hern\u00e1ndez","year":"2018","journal-title":"Mem\u00f3rias do Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib36","article-title":"Clinical and pharmacological profile of benznidazole for treatment of Chagas disease","author":"Kratz","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijpddr.2019.11.004_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2958.2000.01721.x","article-title":"Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress","volume":"35","author":"Krieger","year":"2002","journal-title":"Mol. Microbiol."},{"issue":"9","key":"10.1016\/j.ijpddr.2019.11.004_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00127-17","article-title":"Genetic adjuvantation of a cell-based therapeutic vaccine for amelioration of chagasic cardiomyopathy","volume":"85","author":"Konduri","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2013.01.008","article-title":"Further evidence of the trypanocidal action of eupomatenoid-5: confirmation of involvement of reactive oxygen species and mitochondria owing to a reduction in trypanothione reductase activity","volume":"60","author":"Lazarin-Bid\u00f3ia","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.ijpddr.2019.11.004_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1590\/0037-8682-0285-2017","article-title":"Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination","volume":"51","author":"Louren\u00e7o","year":"2018","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"17","key":"10.1016\/j.ijpddr.2019.11.004_bib42","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4155\/fmc.13.166","article-title":"A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors","volume":"5","author":"Maluf","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib44","first-page":"1","article-title":"Insights into Chagas treatment based on the potential of bacteriocin AS-48","volume":"10","author":"Mart\u00edn-Escolano","year":"2019","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib45","first-page":"1","article-title":"Benznidazole\/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease","author":"Martins","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijpddr.2019.11.004_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population","volume":"206","author":"Mejia","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2018.11.062","article-title":"Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening","author":"Melo-Filho","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8676578","article-title":"Relevance of trypanothione reductase inhibitors on trypanosoma cruzi infection: a systematic review, meta-analysis, and in silico integrated approach","volume":"2018","author":"Mendon\u00e7a","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.01.013","article-title":"Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti-Trypanosoma cruzi activity","volume":"165","author":"Miana","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib50","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib51","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas' cardiomyopathy","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. 1-13","author":"Oliveira","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopha.2018.10.057","article-title":"In vitro anti-Trypanosoma cruzi activity of ternary copper (II) complexes and in vivo evaluation of the most promising complex","volume":"109","author":"Paix\u00e3o","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib54","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/jm5015742","article-title":"Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents","author":"Papadopoulou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib55","first-page":"424","article-title":"Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study","author":"Perez-Mazliah","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"10115","key":"10.1016\/j.ijpddr.2019.11.004_bib56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-18","article-title":"Role of ascorbic acid as supporting in the therapeutic of Chagas disease: benefits in the association with low dose of benznidazole","author":"Providello","year":"2018","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib58","first-page":"1","article-title":"Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection","author":"Rial","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib59","first-page":"1","article-title":"Impact of levamisole in co-administration with benznidazole on experimental Chagas disease","author":"Rocha Sim\u00f5es-Silva","year":"2019","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1747-0285.2012.01416.x","article-title":"Novel cruzain inhibitors for the treatment of Chagas' disease","author":"Rogers","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib61","first-page":"1","article-title":"Novel scaffolds for inhibition of Cruzipain identified from high through put screening of anti kinetoplastid chemical boxes","author":"Salas-Sarduy","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijpddr.2019.11.004_bib62","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of Chagas disease: a review","volume":"97","author":"Sales Junior","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2016.02.018","article-title":"Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease","author":"Sbaraglini","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/iep.12289","article-title":"Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: reduced intensity of tissue parasitism and inflammation-A histopathological study","author":"Scarim","year":"2018","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib65","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejmech.2018.06.040","article-title":"Current advances in drug discovery for Chagas disease","volume":"155","author":"Scarim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib66","first-page":"1","article-title":"Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi","author":"Sim\u00f5es-Silva","year":"2019","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib67","first-page":"283","article-title":"Chagas's disease: 100 years from its Discovery","author":"Sobrinho","year":"2009","journal-title":"Rev. Bras. Ciencias Farm."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib68","first-page":"103","article-title":"Delineamento de alternativas terap\u00eauticas para o tratamento da doen\u00e7a de Chagas","author":"Sobrinho","year":"2007","journal-title":"J. Trop. Pathol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib69","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1128\/AAC.00070-13","article-title":"In VitroandIn VivoStudies of the antiparasitic activity of sterol 14\u03b1-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi","author":"de Nazar\u00e9 Correia Soeiro","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.parint.2013.02.004","article-title":"Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection","author":"Strauss","year":"2013","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exppara.2018.04.016","article-title":"In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: a multivariate approach","volume":"189","author":"Strauss","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib72","first-page":"1","article-title":"Mode of action of the sesquiterpene lactones psilostachyin and psilostachyin C on Trypanosoma cruzi","author":"S\u00fclsen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.11.004_bib73","first-page":"1","article-title":"Activity of estafietin and analogues on Trypanosoma cruzi and Leishmania braziliensis","author":"S\u00fclsen","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ijpddr.2019.11.004_bib74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.exppara.2016.12.013","article-title":"Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model","author":"Valle-Reyes","year":"2017","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib76","first-page":"1","article-title":"Resveratrol reverses functional Chagas heart disease in mice","author":"Vilar-Pereira","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib77","first-page":"511","article-title":"VNI cures acute and chronic experimental Chagas disease","volume":"504","author":"Villalta","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib78","first-page":"1","article-title":"Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B super types in Chagasic chronic patients from Mexico","author":"Villanueva-Lizama","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02515-18","article-title":"A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole","author":"Watson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.ijpddr.2019.11.004_bib80","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijpddr.2019.11.004_bib81","series-title":"Chagas Disease (American Trypanosomiasis)","author":"World Health Organization","year":"2018"}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719301447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719301447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:48:46Z","timestamp":1761922126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320719301447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":79,"alternative-id":["S2211320719301447"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.11.004","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current trends in the pharmacological management of Chagas disease","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}